Pancreatic Cancer Research

ResearcherFirst Affiliated Hospital of Nanchang UniversityActive in the last 2 years

Jianping Xiong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0398-6090; OpenAlex author ID A5068044246. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
39
Papers, trials and grants by year

2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 11

  1. [Retracted] Ruscogenin induces ferroptosis in pancreatic cancer cells. Last author DOI 10.3892/or.2025.8863↗
  2. Upregulated GPRC5A disrupting the Hippo pathway promotes the proliferation and migration of pancreatic cancer cells via the cAMP-CREB axis. Co-author DOI 10.1007/s12672-023-00626-1↗
  3. Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer. Co-author DOI 10.1016/j.jncc.2022.08.006↗
  4. LINC01128 facilitates the progression of pancreatic cancer through up-regulation of LDHA by targeting miR-561-5p. Co-author DOI 10.1186/s12935-022-02490-5↗
  5. Silencing LINC00491 Inhibits Pancreatic Cancer Progression through MiR-188-5p-induced Inhibition of ZFP91. Co-author DOI 10.7150/jca.65071↗
  6. LDLRAD2 promotes pancreatic cancer progression through Akt/mTOR signaling pathway. Co-author DOI 10.1007/s12032-020-01451-0↗
  7. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma. Last author DOI 10.1111/jcmm.16480↗
  8. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression. Co-author DOI 10.1186/s13046-020-01660-5↗
  9. Ruscogenin induces ferroptosis in pancreatic cancer cells. Last author DOI 10.3892/or.2019.7425↗
  10. MiR-708-5p inhibits the progression of pancreatic ductal adenocarcinoma by targeting Sirt3. Last author DOI 10.1016/j.prp.2019.01.026↗
  11. UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization. Last author PMID 31598398↗

Closest collaborators

The 25 strongest of 39 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Zhiwang Song · 7 shared papers, 2019–2025 · strength 1.22
  2. Junhe Li · 7 shared papers, 2019–2025 · strength 1.16
  3. Zhi Fang Ma · 2 shared papers, 2022 · strength 0.37
  4. Min Zhong · 2 shared papers, 2022 · strength 0.37
  5. Qing Han · 2 shared papers, 2020–2021 · strength 0.33
  6. Shanshan Huang · 2 shared papers, 2019–2021 · strength 0.26
  7. Weidan Fang · 1 shared paper, 2023 · strength 0.22
  8. Xin Yu · 1 shared paper, 2023 · strength 0.22
  9. Mei Ma · 1 shared paper, 2023 · strength 0.22
  10. Yanxia Jiang · 1 shared paper, 2022 · strength 0.19
  11. Jun Chen · 1 shared paper, 2021 · strength 0.12
  12. Feng Jiao · 1 shared paper, 2022 · strength 0.09
  13. Zheng Wang · 1 shared paper, 2022 · strength 0.09
  14. Zhiwei Li · 1 shared paper, 2022 · strength 0.09
  15. Tao Zhang · 1 shared paper, 2022 · strength 0.09
  16. Qingyong Ma · 1 shared paper, 2022 · strength 0.09
  17. Liwei Wang · 1 shared paper, 2022 · strength 0.09
  18. Chunyi Hao · 1 shared paper, 2022 · strength 0.09
  19. Gang Ren · 1 shared paper, 2022 · strength 0.09
  20. Jie Chen · 1 shared paper, 2022 · strength 0.09
  21. Dan Cao · 1 shared paper, 2022 · strength 0.09
  22. Jian Wang · 1 shared paper, 2022 · strength 0.09
  23. Yongrui Bai · 1 shared paper, 2022 · strength 0.09
  24. Zhihong Zhang · 1 shared paper, 2022 · strength 0.09
  25. Yongwei Sun · 1 shared paper, 2022 · strength 0.09

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.